Gelly F, Chambon O, Marie-Cardine M
Interne des Hôpitaux, SHU de Psychiatrie, CHS du Vinatier, Bron.
Encephale. 1997 Sep-Oct;23(5):385-96.
This study reports a clinical experience among twenty schizophrenic patients treated by clozapine during two years and eight months within a range extending from three months to seven years. These twenty patients had previously shown long-term resistance to usual neuroleptics but three out of them met the diagnosis of mental retardation or childhood disintegrative disorder (F.84.3-ICD 10). These patients were put under clozapine for their violent behavior. The methodology was retrospective, descriptive with intra-individual comparison, each patient being his own reference before and after treatment. Diagnosis met CD 10 criteria and were assessed without using standard examination. This study aimed at assessing once more clozapine efficacy and tolerance upon a long time follow up. Single therapy has been the rule and dosages have been progressively increased reaching a mean daily dosage of 350 mg per day. The efficacy, assessed by the way of BPRS, GAF (DSM III-R) and simplified form of CGIS, has been verified in approximately 30% of the patients, mainly concerning positive symptoms. Clozapine was also able to alleviate severe behavior troubles brought about by delusional states, without this latter being markedly softened when it was a long term one. Clozapine tolerance has shown it to be satisfactory, however we noticed the occurrence of a leucopenia with neutropenia after seventeen weeks of treatment, followed, some days later, by a Quincke oedema, which forced to interrupt the treatment. White blood cells came back in a normal range fifteen days later. The other side effects (transitory hypersialorrhea, tachycardia, without clinical and ECG perturbations) have been usually well tolerated and have never caused treatment interruption. No extrapyramidal side effect have been noticed among our twenty patients. The end of this paper consists in the presentation of four clinical cases: one about the efficacy of clozapine upon violent antisocial behaviour in a schizotypital disorder; one delusional chronic schizophrenic patient whose violence has been controlled despite of the delusion; one paranoid schizophrenic patient who has been able to maintain a satisfactory professional and family adaptation; and finally a childhood disintegrative disorder (F.84.3-ICD 10) in whom occurred the only leucopenia side effect of our study. These four clinical cases have seemed particularly meaningful regarding our clinical experience of clozapine which has been lasting for almost seven years now.
本研究报告了20例精神分裂症患者在两年零八个月内使用氯氮平治疗的临床经验,治疗时间跨度从三个月至七年不等。这20例患者此前对常用抗精神病药物长期耐药,但其中3例符合精神发育迟滞或儿童期瓦解性障碍的诊断(国际疾病分类第10版,F.84.3)。这些患者因暴力行为接受氯氮平治疗。研究方法为回顾性、描述性且进行个体内比较,每位患者在治疗前后均以自身作为对照。诊断符合国际疾病分类第10版标准,且未采用标准检查进行评估。本研究旨在通过长期随访再次评估氯氮平的疗效和耐受性。治疗原则为单一用药,剂量逐渐增加,平均日剂量达到350毫克。通过简明精神病评定量表(BPRS)、大体功能评定量表(GAF,《精神疾病诊断与统计手册》第三版修订版)和临床总体印象量表简化版(CGIS)评估疗效,约30%的患者疗效得到验证,主要涉及阳性症状。氯氮平还能够缓解妄想状态引发的严重行为问题,然而,对于长期存在的妄想状态,其缓解效果并不显著。氯氮平的耐受性表现令人满意,不过我们注意到,治疗17周后出现了白细胞减少伴中性粒细胞减少的情况,数天后又出现了昆克水肿,这迫使治疗中断。15天后白细胞计数恢复至正常范围。其他副作用(短暂性流涎过多、心动过速,但无临床及心电图异常)通常耐受性良好,从未导致治疗中断。在我们的20例患者中未发现锥体外系副作用。本文结尾呈现了4个临床病例:1例关于氯氮平对分裂型障碍中暴力反社会行为的疗效;1例慢性妄想型精神分裂症患者,尽管存在妄想,但其暴力行为得到控制;1例偏执型精神分裂症患者能够维持令人满意的职业和家庭适应状态;最后1例为儿童期瓦解性障碍(国际疾病分类第10版,F.84.3)患者,其出现了本研究中唯一的白细胞减少副作用。就我们长达近七年的氯氮平临床经验而言,这4个临床病例似乎具有特别重要的意义。